EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity

Chitra Saran iD, Kim L R Brouwer

Toxicologic Pathology · 2023-10 · 51 (7-8) · 405-413

DOI: 10.1177/01926233231212255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 20.11.2023. Verfasst von Chitra Saran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Transporter Sciences, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB), Merck & Co., Inc., West Point, Pennsylvania, USA. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions, Carrier Proteins, Membrane Glycoproteins. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced liver injury (DILI) remains a major concern in drug development from a patient safety perspective because it is the leading cause of acute liver failure. One mechanism of DILI is altered bile acid homeostasis and involves several hepatic bile acid transporters. Functional impairment of some hepatic bile acid transporters by drugs, disease, or genetic mutations may lead to toxic accumulation of bile acids within hepatocytes and increase DILI susceptibility. This review focuses on the role of hepatic bile acid transporters in DILI. Model systems, primarily in vitro and modeling tools, such as DILIsym, used in assessing transporter-mediated DILI are discussed. Due to species differences in bile acid homeostasis and drug-transporter interactions, key aspects and challenges associated with the use of preclinical animal models for DILI assessment are emphasized. Learnings are highlighted from three case studies of hepatotoxic drugs: troglitazone, tolvaptan, and tyrosine kinase inhibitors (dasatinib, pazopanib, and sorafenib). The development of advanced in vitro models and novel biomarkers that can reliably predict DILI is critical and remains an important focus of ongoing investigations to minimize patient risk for liver-related adverse reactions associated with medication use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryDrug-Related Side Effects and Adverse ReactionsCarrier ProteinsMembrane GlycoproteinsAnimalsHumansBile Acids and Salts

Stichwörter der Autor:innen

Hepatic transportersbile acidsdrug-induced liver injuryhepatotoxicitykinase inhibitorstolvaptantroglitazone

Substanzen

bile acid binding proteinsBile Acids and SaltsCarrier ProteinsMembrane Glycoproteins

Autor:innen und Institutionen

  • Transporter Sciences, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB), Merck & Co., Inc., West Point, Pennsylvania, USA.
  • UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Chitra Saran

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Saran, C., & Brouwer, K. L. R. (2023). Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity. Toxicologic Pathology, 51(7-8), 405-413. https://doi.org/10.1177/01926233231212255

Vancouver

Saran C, Brouwer KLR. Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity. Toxicologic Pathology. 2023;51(7-8):405-413. doi:10.1177/01926233231212255

BibTeX
@article{Saran2023,
  author = {Saran, Chitra and Brouwer, Kim L R},
  title = {Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity},
  journal = {Toxicologic Pathology},
  year = {2023},
  volume = {51},
  number = {7-8},
  pages = {405--413},
  doi = {10.1177/01926233231212255}
}
Kostenlos starten →